Table 1. Baseline characteristics at SJS diagnosis, stratified by AKI Status.
| Variable | All patients | AKI | Non-AKI | P value |
|---|---|---|---|---|
| Patient number | 75 | 23 | 52 | - |
| Age, y | 64 (31) | 75 (14) | 58 (33) | < 0.001 |
| Male sex, n (%) | 34 (45.3) | 10 (43.5) | 24 (46.2) | 1.000 |
| Underlying disease, n (%) | ||||
| Diabetes mellitus | 27 (36.0) | 12 (52.2) | 15 (28.8) | 0.069 |
| Chronic kidney disease | 17 (22.7) | 15 (65.2) | 2 (3.8) | < 0.001 |
| Chronic liver disease | 6 (8.0) | 2 (8.7) | 4 (7.7) | 1.000 |
| Cancer/hematologic malignancy | 8 (10.7) | 5 (21.7) | 3 (5.8) | 0.053 |
| Gout | 9 (12.0) | 7 (30.4) | 2 (3.8) | 0.003 |
| Mean arterial pressure, mmHg | 95 (26) | 88 (31) | 97 (24) | 0.095 |
| APACHE II | 8 (7) | 14 (7) | 7 (3) | < 0.001 |
| APACHE III | 28 (30) | 53 (25) | 22 (15) | < 0.001 |
| SOFA | 1 (3) | 4 (4) | 1 (2) | < 0.001 |
| SCORTEN | 2 (1) | 3 (1) | 2 (1) | < 0.001 |
| Lab data | ||||
| Leukocyte count, 1000/mL | 8.0 (5.3) | 8.9 (5.9) | 7.5 (4.9) | 0.260 |
| Hemoglobin, g/dL | 12.6 (3.3) | 9.4 (3.7) | 13.0 (2.2) | <0.001 |
| Platelet count, 1000/mL | 185 (100) | 197 (100) | 185 (86) | 0.662 |
| Bilirubin, mg/dL | 0.5 (0.4) | 0.5 (0.4) | 0.5 (0.5) | 0.917 |
| Creatinine, mg/dL | 0.92 (1.13) | 2.25 (2.38) | 0.73 (0.48) | <0.001 |
| BUN, mg/dL | 17.0 (25.7) | 53.2 (38.3) | 11.2 (8.6) | <0.001 |
| Albumin, mg/dL | 3.3 (1.0) | 2.7 (1.0) | 3.5 (0.7) | <0.001 |
| Sodium, mg/dL | 137 (5) | 137 (6) | 137 (5) | 0.416 |
| Potassium, mg/dL | 4.2 (0.7) | 4.5 (1.0) | 4.0 (0.7) | 0.020 |
Continuous data are presented as median (interquartile range).
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; BUN, blood urea nitrogen; SCORTEN, severity-of-illness for toxic epidermal necrolysis; SJS, Stevens–Johnson syndrome; SOFA, sequential organ failure assessment score.